WSTAM
NBIX icon

Wilbanks Smith & Thomas Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-195
Closed -$24K – 964
2018
Q3 		$24K Buy
+195
New +$22.1K ﹤0.01% 846

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's NBIX Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 195 shares — an estimated $24K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in NBIX in Q3 2018 and held it in 1 quarter. The position peaked at $24K in Q3 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 195 Neurocrine Biosciences shares in Q4 2018, an estimated $24K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Neurocrine Biosciences position peaked at $24K in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.